Related Experiment Videos
[Changes of immunologic function in patients with COPD induced chronic cor pulmonale]
Zhonghua Nei Ke Za Zhi
|November 1, 1993
Summary
Chronic cor pulmonale patients show decreased CD4+ T-cells during exacerbations. Thymopeptide treatment improved lymphocyte counts and immune function in these patients, suggesting a therapeutic role.
Area of Science:
- Immunology
- Pulmonology
- Cell Biology
Context:
- Chronic obstructive pulmonary disease (COPD) can lead to chronic cor pulmonale, a serious complication affecting the heart.
- Immune system dysregulation, particularly involving lymphocyte subpopulations, is implicated in the pathogenesis and progression of COPD-induced chronic cor pulmonale.
- Understanding changes in lymphocyte subsets like CD3+, CD4+, CD8+, and CD16+ is crucial for assessing disease severity and treatment efficacy.
Purpose:
- To investigate the alterations in peripheral blood lymphocyte (PBL) subpopulations (CD3+, CD4+, CD8+, CD16+) and humoral immunological parameters (HIP) in patients with COPD-induced chronic cor pulmonale.
- To evaluate the impact of treatment, including thymopeptide, on these immunological markers during exacerbation and remission stages.
- To explore correlations between lymphocyte counts, immunological parameters, and gas exchange (PaO2).
Summary:
- During exacerbation, patients exhibited significantly decreased CD3+, CD4+, CD16+ counts, and a lower CD4+:CD8+ ratio, correlating with reduced PaO2. Humoral parameters showed elevated IgE and Circulating Immune Complex (CIC) levels, with lower C3. Post-treatment, lymphocyte counts improved, but HIP remained unchanged.
- In remission, only CD4+ levels were reduced. Thymopeptide treatment increased CD4+ counts, decreased CD8+ counts, and raised the CD4+:CD8+ ratio, alongside increased serum IgA and CIC levels.
- These findings indicate significant immune modulation in COPD-induced chronic cor pulmonale, with thymopeptide demonstrating a regulatory effect on immune function.
Impact:
- Highlights the role of specific lymphocyte subpopulations in the pathophysiology of COPD-induced chronic cor pulmonale.
- Provides evidence for the immunomodulatory effects of thymopeptide in managing immune dysregulation associated with this condition.
- Suggests potential for monitoring lymphocyte profiles and utilizing immunomodulatory therapies for improved patient outcomes.